---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-040414"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2026-04-07T23:59:59+00:00"
generated_at: "2026-05-15T06:58:45.045081+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Fennec announces Univ of Arizona investigator-sponsored study of PEDMARK in AYA & adult cisplatin patients

## Summary
- Phase I/II study by University of Arizona Cancer Center to evaluate PEDMARK for preventing cisplatin-induced ototoxicity in head and neck and testicular cancer patients.
- Study builds on two other recent investigator-initiated trials: Tampa General Hospital (Mar 2026) and City of Hope (Dec 2025) in AYA and adult populations.
- Fennec CMO states data will support broader clinical adoption and potential label expansion for PEDMARK beyond pediatric approval.
- PEDMARK is currently approved for pediatric patients with localized non-metastatic solid tumors and has NCCN 2A recommendation for AYA patients.

## SEC filing metadata
- accession: 0001104659-26-040414
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2026-04-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000110465926040414/0001104659-26-040414-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000110465926040414/fencf-20260407x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-040414
- JSON: https://secwatch.observer/filing/0001104659-26-040414.json
- Plain text: https://secwatch.observer/filing/0001104659-26-040414.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.